scholarly journals Elevations of AGE and vascular endothelial growth factor with decreased total antioxidant status in the vitreous fluid of diabetic patients with retinopathy

2005 ◽  
Vol 89 (6) ◽  
pp. 673-675 ◽  
Author(s):  
M Yokoi
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Antioxidant Status ◽  
Total Antioxidant Status ◽  
Diabetic Patients ◽  
Vascular Endothelial ◽  
Vitreous Fluid ◽  
Total Antioxidant ◽  
Endothelial Growth Factor

scholarly journals The Role of Focal Laser in the Anti–Vascular Endothelial Growth Factor Era

2017 ◽  
Vol 9 ◽  
pp. 117917211773824 ◽  
Author(s):  
Jason N Crosson ◽  
Lauren Mason ◽  
John O Mason
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Visual Acuity ◽  
Growth Factor ◽  
Macular Edema ◽  
Real World ◽  
Pharmacologic Therapy ◽  
Diabetic Patients ◽  
Vascular Endothelial ◽  
Real World Data ◽  
Endothelial Growth Factor

Introduction: To review important studies examining focal laser for diabetic macular edema (DME), to examine real-world data regarding actual treatments patients are receiving, to present long-term visual outcomes in real-world practice, and to suggest an evidence-based approach for the use of focal laser. Methods: This study is a review of landmark studies evaluating focal laser and pharmacologic therapy for DME. In addition, the authors include a retrospective review of 102 consecutive eyes of 53 patients in our practice setting in rural Alabama. A chart review was performed, and patients were included if they were diagnosed with DME and were treated with both focal laser and bevacizumab. Bevacizumab and focal laser were given on a “as needed basis” at the discretion of one treating physician (J.O.M.). Worse visual acuity or worsening macular edema were indications for additional treatment. Statistical analysis was performed using frequencies and percentages. Best-corrected visual acuity (BCVA) was recorded at baseline and at the end of treatment (mean of 5 years) in the medical record. Primary outcome measures were BCVA, patients with better than 20/40 BCVA, patients with worse than 20/200 BCVA, and patients with stable BCVA. Results: Anti–vascular endothelial growth factor (VEGF) therapies are the first-line treatment for DME, but real-world claims data suggest that diabetic patients cannot come in for monthly injections as in large clinical trials. In our series, after a mean of 5 lasers and 5.5 injections, 90% of eyes had stable or better BCVA, 65% were ≥20/40, and only 13% were ≤20/200. Conclusions: Laser treatment for DME remains an important adjunctive therapy

Plasma Total Antioxidant Activity in Comparison with Plasma NO and VEGF Levels in Patients with Metabolic Syndrome

Angiology ◽  
2008 ◽  
Vol 60 (1) ◽  
pp. 87-92 ◽  
Author(s):  
Marcin Barylski ◽  
Edward Kowalczyk ◽  
Maciej Banach ◽  
Julita Ciećwierz ◽  
Lucjan Pawlicki ◽  
...  
Keyword(s):  
Nitric Oxide ◽  
Metabolic Syndrome ◽  
Vascular Endothelial Growth Factor ◽  
Antioxidant Activity ◽  
Growth Factor ◽  
Vascular Endothelial ◽  
Total Antioxidant Activity ◽  
Total Antioxidant ◽  
Endothelial Growth Factor ◽  
Healthy Participants

Introduction The aim of our study was to estimate plasma antioxidant activity as well as plasma nitric oxide (NO) and vascular endothelial growth factor levels in patients with metabolic syndrome compared with healthy participants. Material and Methods Fifty patients (24 women and 26 men, mean age 55.9 ± 11.8 years) with metabolic syndrome were compared with 25 healthy participants (12 women and 13 men, mean age 54.2 ± 12.8 years). Plasma total antioxidant activity and plasma levels of NO and VEGF were determined in all participants. Results In the patients with metabolic syndrome, plasma total antioxidant activity, nitric oxide, and vascular endothelial growth factor were significantly lower ( P < .001) than that observed in healthy participants (3.2 ± 1.6 vs 6.4 ± 2.1 mM/L), (6.3 ± 2.2 vs 9.8 ± 2.7 μM/L), and 71.0 ± 16.9 vs 137.5 ± 12.6 pg/mL), respectively. Conclusions Decreased plasma total antioxidant activity, NO, and VEGF levels in patients with metabolic syndrome reflect significant endothelial dysfunction. This suggests that oxidation–reduction balance disorders might play an important role in this process

Sign in / Sign up

Export Citation Format

Share Document